Half-year report · HY
2342.TEDINET S100WYWR
Period2025-04-01 → 2025-09-30
Filed2025-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥6.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥13.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥6.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥71m | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | −¥111m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥83m | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | −¥320m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥157m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥57m | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | −¥195m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥30m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥182m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥11m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | −¥185m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥9.6bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥9.6bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥10.6bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥4.8bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥4.7bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥4.9bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥4.9bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥5.8bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.2bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.6bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.2bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.5bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.2bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.5bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥569m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥94m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥421m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥36m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥288m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥175m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥261m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥265m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥379m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥1.77 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-65.51 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-10.97 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 49.8% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 49.7% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.5% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥3m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥3m |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥98m |
| Drug Discovery Support Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥938m |
| Drug Discovery Support Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥935m |
| Drug Discovery Support Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥3m |
| Drug Discovery Support Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥75m |
| Investments And Consulting Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥5.3bn |
| Investments And Consulting Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥5.3bn |
| Investments And Consulting Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥62,000 |
| Investments And Consulting Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥245m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥6.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥6.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥3m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥170m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥3m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥3m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥114m |
| Drug Discovery Support Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥806m |
| Drug Discovery Support Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥803m |
| Drug Discovery Support Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥3m |
| Drug Discovery Support Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥189m |
| Investments And Consulting Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥5.5bn |
| Investments And Consulting Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥5.5bn |
| Investments And Consulting Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥45,000 |
| Investments And Consulting Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥192m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥6.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥6.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥3m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥3m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 508
| Item | Context | Value | Unit |
|---|---|---|---|
| Provision for loss on order received cl | Prior1YearInstant | 61989000 | JPY |
| Provision for loss on order received cl | InterimInstant | 1105000 | JPY |
| Other cl | Prior1YearInstant | 212508000 | JPY |
| Other cl | InterimInstant | 110251000 | JPY |
| Current liabilities | Prior1YearInstant | 3272076000 | JPY |
| Current liabilities | InterimInstant | 3532953000 | JPY |
| Bonds payable | Prior1YearInstant | 109000000 | JPY |
| Bonds payable | InterimInstant | 50000000 | JPY |
| Long term loans payable | Prior1YearInstant | 1247401000 | JPY |
| Long term loans payable | InterimInstant | 1105091000 | JPY |
| Net defined benefit liability | Prior1YearInstant | 68774000 | JPY |
| Net defined benefit liability | InterimInstant | 67651000 | JPY |
| Other ncl | Prior1YearInstant | 32965000 | JPY |
| Other ncl | InterimInstant | 25465000 | JPY |
| Noncurrent liabilities | Prior1YearInstant | 1458140000 | JPY |
| Noncurrent liabilities | InterimInstant | 1248208000 | JPY |
| Liabilities | Prior1YearInstant | 4730217000 | JPY |
| Liabilities | InterimInstant | 4781161000 | JPY |
| Capital stock | Prior1YearInstant | 50000000 | JPY |
| Capital stock | InterimInstant | 50000000 | JPY |
| Capital surplus | Prior1YearInstant | 3857377000 | JPY |
| Capital surplus | InterimInstant | 3856375000 | JPY |
| Retained earnings | Prior1YearInstant | 927674000 | JPY |
| Retained earnings | InterimInstant | 957222000 | JPY |
| Treasury stock | Prior1YearInstant | -116016000 | JPY |
| Treasury stock | InterimInstant | -116016000 | JPY |
| Shareholders equity | Prior1YearInstant | 4719036000 | JPY |
| Shareholders equity | InterimInstant | 4747581000 | JPY |
| Valuation difference on available for sale securities | Prior1YearInstant | 18817000 | JPY |
| Valuation difference on available for sale securities | InterimInstant | 18313000 | JPY |
| Foreign currency translation adjustment | Prior1YearInstant | 24657000 | JPY |
| Foreign currency translation adjustment | InterimInstant | 33903000 | JPY |
| Valuation and translation adjustments | Prior1YearInstant | 43474000 | JPY |
| Valuation and translation adjustments | InterimInstant | 52217000 | JPY |
| Subscription rights to shares | Prior1YearInstant | 200000 | JPY |
| Subscription rights to shares | InterimInstant | 200000 | JPY |
| Non controlling interests | Prior1YearInstant | 93470000 | JPY |
| Non controlling interests | InterimInstant | 60977000 | JPY |
| Net assets | Prior1YearInstant | 4856181000 | JPY |
| Net assets | InterimInstant | 4860976000 | JPY |
| Liabilities and net assets | Prior1YearInstant | 9586399000 | JPY |
| Liabilities and net assets | InterimInstant | 9642137000 | JPY |
| Net sales | Prior1InterimDuration | 6311881000 | JPY |
| Net sales | InterimDuration | 6224853000 | JPY |
| Cost of sales | Prior1InterimDuration | 5197343000 | JPY |
| Cost of sales | InterimDuration | 5001037000 | JPY |
| Gross profit | Prior1InterimDuration | 1114537000 | JPY |
| Gross profit | InterimDuration | 1223815000 | JPY |
| Selling general and administrative expenses | Prior1InterimDuration | 1225307000 | JPY |
| Selling general and administrative expenses | InterimDuration | 1152410000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |